Abuse of recombinant erythropoietins by athletes - Erythropoietins and Erythropoiesis - page 222

64 Emslie KR, Howe C, Trout G (1999) Measurement of urinary erythropoietin levels in athletes. In :
W Schänzer, H Geyer, A Gotzmann, U Mareck-Engelke (eds): Recent advances in doping analy-
sis (7). Proceedings of the Manfred Donike Workshop, 17th Cologne Workshop on Dope Analysis,
14th to 19th March 1999, Sport & Buch Strauss , Cologne, 291-300
65 Wide L, Bengtsson C, Berglund B, Ekblom B (1995) Detection in blood and urine of recombinant
erythropoietin administered to healthy men. Med Sci Sports Exerc 27: 1569-1576
66 Skibeli V, Nissen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoi-
etin differs from recombinant human erythropoietin. Blood 98: 3626-3634
67 Lasne F, de Ceaurriz J (2000) Recombinant erythropoietin in urine. Nature 405:635
68 Lasne F (2001) Double-blotting: A solution to the problem of non-specific binding of secondary
antibodies in immunoblotting procedures. J Immunol Methods 253:125-131
69 Lasne F, Martin L, Crepin N, de Ceaurriz J (2002) Detection of isoelectric profiles of erythropoi-
etin in urine: Differentiation of natural and administered recombinant hormones. Anal Biochem
311: 119-126
70 Catlin DH, Breidbach A, Elliott S, Glaspy J (2002) Comparison of isoelectric focusing patterns of
darbepoetin alfa, recombinant human erythropoietin and endogenous erythropoietin from human
urine. Clin Chem 48: 2057-2059
71 Egrie J, Browne J (2002) Darbepoetin alfa is more potent in vivo and can be administered less fre-
quently than rHuEPO. Br J Cancer 87: 476-477
72 International Olympic Committee Medical Commission (2002) Post Games Report - Salt Lake
City, Phase 4. CAFDIS-antidoping.net. http://www.cafdis-antidoping.net./en/article.asp?arti-
cleid=273&page=5 . Accessed 10-1-2002
73 Macdougall IC (2002) Optimizing the use of erythropoietic agents - pharmacokinetic and phar-
macodynamic considerations. Nephrol Dial Transplant 17 Suppl 5: 66-70
74 Parisotto R, Gore CJ, Hahn AG, Ashenden MJ, Olds TS, Martin DT, Pyne DB, Gawthorn K (2000)
Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in
elite athletes. Int J Sports Med 21: 471-479
75 Bren A, Kandus A, Varl J, Buturovic J, Ponikvar R, Kveder R, Primozic S, Ivanovich P (2002) A
comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis
patients: A prospective, controlled crossover study. Artif Organs 26: 91-97
76 Sikole A, Spasovski G, Zafirov D, Polenakovic M (2002) Epoetin omega for treatment of anemia
in maintenance hemodialysis patients. Clin Nephrol 57: 237-245
77 Dragon Pharmaceuticals Inc., Technology Platform, http://www.dragonbiotech.com/

technology.asp?pn=1. Accessed 10-18-2002
78 Bulman E (2001) IOC prepares for possible future genetic cheating. Nando Media Jun 2; Sect.
Sports